In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization

被引:7
作者
Gilabert-Oriol, Roger [1 ]
Chernov, Lina [1 ]
Anantha, Malathi [1 ]
Dragowska, Wieslawa H. [1 ]
Bally, Marcel B. [1 ,2 ,3 ,4 ]
机构
[1] BC Canc Agcy, Expt Therapeut, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada
[2] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada
[3] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada
[4] Ctr Drug Res & Dev, Vancouver, BC, Canada
基金
加拿大健康研究院;
关键词
Topotecan; Lipid nanoparticles; Liposomes; Real time; Drug release; Fluorescence; Neuroblastoma; OVARIAN-CANCER; DRUG; DELIVERY; VIVO; ENCAPSULATION; COMBINATION; FORMULATION; IRINOTECAN; BLOOD; PHARMACOKINETICS;
D O I
10.1007/s13346-017-0380-9
中图分类号
TH7 [仪器、仪表];
学科分类号
0804 ; 080401 ; 081102 ;
摘要
Topotecan is a drug that is under investigation for the treatment of neuroblastoma and has been encapsulated into liposomes to improve its therapeutic efficacy. However, liposomal formulations still need to be optimized for drug retention and new techniques to measure drug release are required to better understand this process. Here, a novel in vitro method based on fluorescence de-quenching and an automated microscopy imaging platform were developed for monitoring, in real time, the release of topotecan from a liposomal formulation. Drug release from liposomes was monitored for up to 15 h under different conditions including topotecan concentrations, fetal bovine serum amounts (0-20%), and temperatures (25 and 37 degrees C). A cell-based assay was used to assess liposome association with cells in culture and to quantify amounts of topotecan internalized into cells after release from liposomes. Our results show that the liposomal topotecan concentration had an influence on drug release kinetics: there was a reduction in release rate as a function of increasing concentration. Our data also show that topotecan release from the liposomal formulation was dependent on serum concentration where faster release was observed at higher serum concentrations, and on temperature where faster release was found at 37 degrees C. This real-time liposomal drug release assay allows for better understanding of the factors important in governing release of topotecan. The assay will he essential towards designing liposomal formulations of topotecan (and potentially of other camptothecin derivatives such as irinotecan) with optimized retention times and better therapeutic efficacy for testing in the clinic.
引用
收藏
页码:544 / 557
页数:14
相关论文
共 43 条
[1]   An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes [J].
Abraham, SA ;
Edwards, K ;
Karlsson, G ;
Hudon, N ;
Mayer, LD ;
Bally, MB .
JOURNAL OF CONTROLLED RELEASE, 2004, 96 (03) :449-461
[2]   Peptide-Targeted Liposomes for Selective Drug Delivery: Advantages and Problematic Issues [J].
Accardo, Antonella ;
Morelli, Giancarlo .
BIOPOLYMERS, 2015, 104 (05) :462-479
[3]   Review of the use of topotecan in ovarian carcinoma [J].
Ahmad, T ;
Gore, M .
EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (11) :2333-2340
[4]   SERUM-INDUCED LEAKAGE OF LIPOSOME CONTENTS [J].
ALLEN, TM ;
CLELAND, LG .
BIOCHIMICA ET BIOPHYSICA ACTA, 1980, 597 (02) :418-426
[5]   The liposome-protein corona in mice and humans and its implications for in vivo delivery [J].
Caracciolo, G. ;
Pozzi, D. ;
Capriotti, A. L. ;
Cavaliere, C. ;
Piovesana, S. ;
La Barbera, G. ;
Amici, A. ;
Lagana, A. .
JOURNAL OF MATERIALS CHEMISTRY B, 2014, 2 (42) :7419-7428
[6]  
Chernov L, 2017, CANC MED
[7]   Nigericin-mediated liposome loading of topotecan: Is nigericin a potential drug release regulator? [J].
Cui, JingXia ;
Li, ChunLei ;
Wang, CaiXia ;
Li, YanHui ;
Zhang, Lan ;
Zhang, Li ;
Xiu, Xian ;
Li, YongFeng ;
Wei, Na .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 399 (1-2) :31-36
[8]   The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats [J].
Dadashzadeh, S. ;
Vali, A. M. ;
Rezaie, M. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 353 (1-2) :251-259
[9]   Role of copper gluconate/triethanolamine in irinotecan encapsulation inside the liposomes [J].
Dicko, Awa ;
Tardi, Paul ;
Xie, Xiaowei ;
Mayer, Lawrence .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 337 (1-2) :219-228
[10]   Development of a highly stable and targetable nanoliposomal formulation of topotecan [J].
Drummond, Daryl C. ;
Noble, Charles O. ;
Guo, Zexiong ;
Hayes, Mark E. ;
Connolly-Ingram, Ceirin ;
Gabriel, Bianca S. ;
Hann, Byron ;
Liu, Bin ;
Park, John W. ;
Hong, Keelung ;
Benz, Christopher C. ;
Marks, James D. ;
Kirpotin, Dmitri B. .
JOURNAL OF CONTROLLED RELEASE, 2010, 141 (01) :13-21